Why the study?
Diabetic nephropathy and hepatopathy involve structural and functional disturbances, and the study aimed to evaluate whether conditioned media derived from human Wharton's jelly mesenchymal stem cells could alleviate these complications.
Does hWJ-MSCs-CM improve diabetic nephropathy and hepatopathy in STZ-induced diabetic rats?
Does hWJ-MSCs-CM improve diabetic nephropathy and hepatopathy in STZ-induced diabetic rats?
Human WJ-MSCs-CM may have protective effects on diabetic renal and hepatic complications via regulation of TGF-β and apelin signaling pathways in a rat model.
Answers are grounded in this paper and cite their sources.
hWJ-MSCs-CM effects in diabetic rats warrant clinical caution; leaves open translation pending human trials.
BACKGROUND: Diabetic nephropathy and hepatopathy are health problems described by specific renal and hepatic structure and function disturbances. The protective effects of the stem cell secretome have been shown in several kidney and liver diseases. The current study aims to evaluate the capability of conditioned media derived from human Wharton's jelly mesenchymal stem cells (hWJ-MSCs-CM) to alleviate diabetic complications. METHODS: Twenty Sprague Dawley rats were made diabetic through injection of STZ (60 mg/kg, i.p.). At week 8, diabetic rats were divided into two groups: treated [DM + hWJ-MSCs-CM (500 µl/rat for three weeks, i.p.)] and not treated (DM). At the 11th week, three groups (control, DM, and DM + hWJ-MSCs-CM) were kept in metabolic cages, and urine was collected for 24 h. The serum samples were maintained for measuring fasting blood glucose (FBG) and kidney and liver functional analysis. The left kidney and liver parts were kept at -80 °C to assess apelin and transforming growth factor-beta (TGF-β) expression. The right kidney, pancreas, and liver parts were used for histopathologic evaluation. RESULTS: DM was detected by higher FBG, microalbuminuria, increased albumin/creatinine ratio, and pancreas, renal, and hepatic structural disturbances. Diabetic hepatopathy was determined by increasing liver enzymes and decreasing total bilirubin. The TGF-β gene expression was significantly upregulated in the diabetic kidney and liver tissues. Apelin gene expression was significantly downregulated in the diabetic liver tissue but did not change in kidney tissue. Administration of hWJ-MSCs-CM improved renal and hepatic functional and structural disturbances. Moreover, CM therapy significantly decreased TGF-β expression and enhanced apelin expression in the kidney and liver tissues. CONCLUSION: Human WJ-MSCs-CM may have protective effects on diabetic renal and hepatic complications. These effects may happen through the regulation of TGF-β and apelin signaling pathways.
No takes yet. Share an insight, caveat, or question.
Karimi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: